Center for Computational Imaging and Personalized Diagnostics, Case Western Reserve University, OH, USA.
Department of Population and Quantitative Health Sciences, Case Western Reserve University, OH, USA.
EBioMedicine. 2021 Jul;69:103481. doi: 10.1016/j.ebiom.2021.103481. Epub 2021 Jul 12.
We developed and validated a prognostic and predictive computational pathology risk score (CoRiS) using H&E stained tissue images from patients with early-stage non-small cell lung cancer (ES-NSCLC).
1330 patients with ES-NSCLC were acquired from 3 independent sources and divided into four cohorts D. D comprised 100 surgery treated patients and was used to identify prognostic features via an elastic-net Cox model to predict overall and disease-free survival. CoRiS was constructed using the Cox model coefficients for the top features. The prognostic performance of CoRiS was evaluated on D (N=331), D (N=657) and D (N=242). Patients from D and D which comprised surgery + chemotherapy were used to validate CoRiS as predictive of added benefit to adjuvant chemotherapy (ACT) by comparing survival between different CoRiS defined risk groups.
CoRiS was found to be prognostic on univariable analysis, D (hazard ratio (HR) = 1.41, adjusted (adj.) P = .01) and D (HR = 1.35, adj. P < .001). Multivariable analysis showed CoRiS was independently prognostic, D (HR = 1.41, adj. P < .001) and D (HR = 1.35, adj. P < .001), after adjusting for clinico-pathologic factors. CoRiS was also able to identify high-risk patients who derived survival benefit from ACT D (HR = 0.42, adj. P = .006) and D (HR = 0.46, adj. P = .08).
CoRiS is a tissue non-destructive, quantitative and low-cost tool that could potentially help guide management of ES-NSCLC patients.
Data collection, anlaysis, and computation resources of the research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award numbers: 1U24CA199374-01, R01CA202752-01A1, R01CA208236-01A1, R01 CA216579-01A1, R01 CA220581-01A1, 1U01 CA239055-01. National Center for Research Resources under award number 1 C06 RR12463-01. VA Merit Review Award IBX004121A from the United States Department of Veterans Affairs Biomedical Laboratory Research and Development Service, the DOD Prostate Cancer Idea Development Award (W81XWH-15-1-0558), the DOD Lung Cancer Investigator-Initiated Translational Research Award (W81XWH-18-1-0440), the DOD Peer Reviewed Cancer Research Program (W81XWH-16-1-0329), the Ohio Third Frontier Technology Validation Fund, the Wallace H. Coulter Foundation Program in the Department of Biomedical Engineering and the Clinical and Translational Science Award Program (CTSA) at Case Western Reserve University.
我们开发并验证了一种基于早期非小细胞肺癌（ES-NSCLC）患者的 H&E 染色组织图像的预后和预测计算病理学风险评分（CoRiS）。
从 3 个独立来源获得了 1330 名 ES-NSCLC 患者，并将其分为 4 个队列。队列 D 包括 100 名接受手术治疗的患者，用于通过弹性网络 Cox 模型识别预后特征，以预测总生存期和无病生存期。使用 Cox 模型系数构建 CoRiS。在 D（N=331）、D（N=657）和 D（N=242）上评估 CoRiS 的预后性能。来自 D 和 D 的患者（包括手术+化疗）用于验证 CoRiS 作为预测辅助化疗（ACT）的附加益处的预测因子，通过比较不同 CoRiS 定义的风险组之间的生存情况。
单变量分析发现 CoRiS 具有预后意义，D（风险比（HR）=1.41，调整（adj.）P=.01）和 D（HR=1.35，adj. P<.001）。多变量分析显示，在调整临床病理因素后，CoRiS 是独立的预后因素，D（HR=1.41，adj. P<.001）和 D（HR=1.35，adj. P<.001）。CoRiS 还能够识别出从 ACT 中获益的高危患者，D（HR=0.42，adj. P=.006）和 D（HR=0.46，adj. P=.08）。
CoRiS 是一种组织无损、定量和低成本的工具，可能有助于指导 ES-NSCLC 患者的管理。
本研究报告中报告的研究的数据收集、分析和计算资源由美国国立卫生研究院国家癌症研究所资助，资助编号为：1U24CA199374-01、R01CA202752-01A1、R01CA208236-01A1、R01 CA216579-01A1、R01 CA220581-01A1、1U01 CA239055-01。由美国国立卫生研究院国家中心获得研究资源奖 1 C06 RR12463-01。美国退伍军人事务部生物医学实验室研究和发展服务部的 Merit 审查奖 IBX004121A、国防部前列腺癌创意发展奖（W81XWH-15-1-0558）、国防部肺癌研究员发起的转化研究奖（W81XWH-18-1-0440）、国防部同行评审癌症研究计划（W81XWH-16-1-0329）、俄亥俄州第三前沿技术验证基金、华莱士·H·库尔特基金会在生物医学工程系和临床与转化科学奖（CTSA）在凯斯西储大学。
Zotero 插件
